Recent Updates
Recently added Catalysts

Epanutin Infatabs

Phase 1

Undisclosed | Small molecule | Other |Viatris Inc.|Trials Updated: Jan 28, 2021

Epanutin Infatabs target and mechanism

ModalitySmall molecule

Also known as Epanutin Infatabs (Phenytoin)

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment26

FDA Designations

No designations recorded

Epanutin Infatabs clinical trials

Epanutin Infatabs · 1 trial · 1 indication

Phase 1 1
NCT01355068A Study to Assess if Epanutin Infatabs 50 mg From Germany Are Similar to Dilantin Infatabs 50 mg From AustraliaHealthy
COMPLETED26 Analytics
PHASE1COMPLETED
A Study to Assess if Epanutin Infatabs 50 mg From Germany Are Similar to Dilantin Infatabs 50 mg From Australia
Healthy
NCT0135506826
Unlock trial analytics

Study Endpoints

Primary Endpoints

Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, and 72 hours (hrs) post-dose

Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast).

Maximum Observed Plasma Concentration (Cmax)
0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48 and 72 hrs post-dose

Secondary Endpoints

Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC [0-∞])
0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48 and 72 hrs post-dose
Extrapolated Area Under the Curve (AUC Percent [%] Extrap)
0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48 and 72 hrs post-dose
Plasma Decay Half Life (t1/2)
0 (pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48 and 72 hrs post-dose
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
Treatment AACTIVE_COMPARATOREpanutin Infatabs 50 mg (sourced from Germany), 1 x 50 mg (REFERENCE)
Treatment BEXPERIMENTALDilantin Infatabs 50 mg (sourced from Australia), 1 x 50 mg (TEST)

Interventions

NameTypeDescription
Epanutin Infatabs (Phenytoin)DRUGChewable Tablet, 50 mg, Single dose
Dilantin Infatabs (Phenytoin)DRUGChewable Tablet, 50 mg, Single dose
Unlock Study Design Details

Eligibility Criteria

Age Range21 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy male and/or female subjects between the ages of 21 and 55 years, inclusive. * An informed consent document signed and dated by the subject. Exclusion Criteria: * Evidence or history of clinically significant abnormalities. * Any condition possibly affecting drug abso...

Countries:Singapore
Unlock Eligibility Criteria

Explore more on BiopharmaWatch

Viatris Inc. (VTRS)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with ECompanies A to ZEvery biotech and pharma company we track